ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update
ImmunityBio shares fell 2% to $6.35 after the company said the FDA requested more data for a potential Anktiva label expansion in bladder cancer. The FDA did not require a new clinical trial. Piper Sandler raised its price target to $7, citing strong revenue forecasts. ImmunityBio plans to submit the requested data within 30 days.